Cargando…

Different perspectives and viewpoints on the postoperative management of EGFR-mutant lung cancer

Detalles Bibliográficos
Autores principales:	Nakao, Masayuki, Ichinose, Junji, Matsuura, Yosuke, Okumura, Sakae, Mun, Mingyon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576077/ https://www.ncbi.nlm.nih.gov/pubmed/33241050 http://dx.doi.org/10.21037/atm.2020.04.34

Ejemplares similares

Risk factors for bronchopleural fistula after lobectomy for lung cancer
por: Ichinose, Junji, et al.
Publicado: (2023)

Optimal timing for lung metastasectomy in patients with colorectal cancer
por: Ichinose, Junji, et al.
Publicado: (2022)

Impact of previous upper gastrointestinal cancer surgery on complications after lobectomy for lung cancer
por: Yamamichi, Takashi, et al.
Publicado: (2022)

Detection of EGFR mutations in early-stage lung adenocarcinoma by machine learning-based radiomics
por: Omura, Kenshiro, et al.
Publicado: (2023)

Prognostic Stratification According to Size and Dominance of Radiologic Solid Component in Clinical Stage IA Lung Adenocarcinoma
por: Nakao, Masayuki, et al.
Publicado: (2022)

An extremely rare case of rapidly growing mediastinal well-differentiated liposarcoma with a sclerosing variant: a case report
por: Iwamoto, Naoya, et al.
Publicado: (2020)

Phrenic nerve interposition in a completely portal robotic thymectomy
por: Tamagawa, Satoru, et al.
Publicado: (2023)

The utility of three-dimensional computed tomography for prediction of tumor invasiveness in clinical stage IA lung adenocarcinoma
por: Kawaguchi, Yohei, et al.
Publicado: (2020)

Ultra-late recurrence of non-small cell lung cancer over 10 years after curative resection
por: Sonoda, Dai, et al.
Publicado: (2019)

Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma
por: Kondo, Yasuto, et al.
Publicado: (2022)

Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure
por: Sonoda, Dai, et al.
Publicado: (2020)

Permissible Outcomes of Lobe-Specific Lymph Node Dissection for Elevated Carcinoembryonic Antigen in Non-Small Cell Lung Cancer
por: Kuroda, Hiroaki, et al.
Publicado: (2021)

A 3-dimensional airway model for tracheobronchial surgery
por: Hashimoto, Kohei, et al.
Publicado: (2022)

A rapidly growing mature mediastinal teratoma with a testicular epidermoid cyst and familial Mediterranean fever
por: Omura, Kenshiro, et al.
Publicado: (2019)

Patient-specific simulation for tracheobronchial reconstruction procedures using 3-dimensional operable models: A proof-of-concept study
por: Hashimoto, Kohei, et al.
Publicado: (2022)

Thoracoscopic partial lung resection following pneumonectomy: a report of three cases
por: Goto, Hidenori, et al.
Publicado: (2019)

Thoracoscopic right upper lobectomy in a patient with bronchial and pulmonary vein anomalies
por: Mun, Mingyon, et al.
Publicado: (2020)

Society for Translational Medicine consensus (2019 edition) shows an option for postoperative management of EGFR-mutant lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2020)

One step too far in the right direction: The Society for Translational Medicine 2019 consensus on postoperative management of EGFR-mutant lung cancer
por: Breadner, Daniel, et al.
Publicado: (2020)

Postoperative management for non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Fumihiro, et al.
Publicado: (2020)

Lymph Node Metastases and Prognosis in Left Upper Division Non-Small Cell Lung Cancers: The Impact of Interlobar Lymph Node Metastasis
por: Kuroda, Hiroaki, et al.
Publicado: (2015)

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
por: Lemmon, Christopher, et al.
Publicado: (2020)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Two Perspectives on Dravet Syndrome: Viewpoints from the Clinician and the Caregiver
por: Bluvstein, Judith, et al.
Publicado: (2023)

Implications of the success of EGFR-targeted therapy in advanced non–small cell lung cancer for its application to the adjuvant setting
por: Takeda, Masayuki
Publicado: (2020)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
por: Olivier, Timothée, et al.
Publicado: (2022)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Prognostic Significance of Tumor Size of Small Lung Adenocarcinomas Evaluated with Mediastinal Window Settings on Computed Tomography
por: Sakao, Yukinori, et al.
Publicado: (2014)

Viewpoints on the PRIOR statement—a reporting guideline for overviews of reviews
por: Yang, Nan, et al.
Publicado: (2023)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Endpoints and viewpoints on spatial neglect
por: McIntosh, Robert D., et al.
Publicado: (2022)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

EGFR and non-small cell lung cancer: implications for surgical practice
por: Varela, Gonzalo, et al.
Publicado: (2020)

Adjuvant TKI treatment of EGFR-mutant lung cancer—already ripe for decision?
por: Kauffmann-Guerrero, Diego
Publicado: (2020)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?
por: Melosky, Barbara
Publicado: (2023)

Introducing the Viewpoint
por: Pugh, Edward N.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u24v10a8pvjjp2pj1o5lo781i9